Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129,180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Mittendorf EA, et al. Among authors: zhang h. Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20. Lancet. 2020. PMID: 32966830 Clinical Trial.
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Huober J, Barrios CH, Niikura N, Jarząb M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H; IMpassion050 Trial Investigators. Huober J, et al. Among authors: zhang h. J Clin Oncol. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28. J Clin Oncol. 2022. PMID: 35763704 Free PMC article. Clinical Trial.
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Murthy RK, et al. Among authors: zhang h. Clin Breast Cancer. 2018 Dec;18(6):e1283-e1288. doi: 10.1016/j.clbc.2018.07.008. Epub 2018 Jul 10. Clin Breast Cancer. 2018. PMID: 30077429 Clinical Trial.
The genomic landscape of metastatic histologic special types of invasive breast cancer.
Pareja F, Ferrando L, Lee SSK, Beca F, Selenica P, Brown DN, Farmanbar A, Da Cruz Paula A, Vahdatinia M, Zhang H, Zoppoli G, Wen HY, Brogi E, Robson ME, Razavi P, Chandarlapaty S, Weigelt B, Reis-Filho JS. Pareja F, et al. Among authors: zhang h. NPJ Breast Cancer. 2020 Oct 14;6:53. doi: 10.1038/s41523-020-00195-4. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 33083532 Free PMC article.
The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
Verdial FC, Mamtani A, Pawloski KR, Sevilimedu V, D'Alfonso TM, Zhang H, Gemignani ML, Barrio AV, Morrow M, Tadros AB. Verdial FC, et al. Among authors: zhang h. Ann Surg Oncol. 2022 Jun;29(6):3810-3819. doi: 10.1245/s10434-022-11367-w. Epub 2022 Mar 5. Ann Surg Oncol. 2022. PMID: 35246810 Free PMC article.
Molecular determinants of post-mastectomy breast cancer recurrence.
Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Keene KS, et al. Among authors: zhang h. NPJ Breast Cancer. 2018 Oct 12;4:34. doi: 10.1038/s41523-018-0089-z. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30345349 Free PMC article.
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
da Silva EM, Selenica P, Vahdatinia M, Pareja F, Da Cruz Paula A, Ferrando L, Gazzo AM, Dopeso H, Ross DS, Bakhteri A, Riaz N, Chandarlapaty S, Razavi P, Norton L, Wen HY, Brogi E, Weigelt B, Zhang H, Reis-Filho JS. da Silva EM, et al. Among authors: zhang h. NPJ Breast Cancer. 2021 Apr 16;7(1):43. doi: 10.1038/s41523-021-00250-8. NPJ Breast Cancer. 2021. PMID: 33863915 Free PMC article.
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
Xu B, Li W, Zhang Q, Shao Z, Li Q, Wang X, Li H, Sun T, Yin Y, Zheng H, Feng J, Zhang H, Lei G, Restuccia E. Xu B, et al. Among authors: zhang q, zhang h. Breast Cancer Res Treat. 2020 Aug;182(3):689-697. doi: 10.1007/s10549-020-05728-w. Epub 2020 Jun 20. Breast Cancer Res Treat. 2020. PMID: 32564260 Free PMC article. Clinical Trial.
129,180 results
You have reached the last available page of results. Please see the User Guide for more information.